These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32432431)

  • 21. [Utilization of hormone replacement therapy in Spain: Trends in the period 2000-2014].
    Baladé Martínez L; Montero Corominas D; Macías Saint-Gerons D
    Med Clin (Barc); 2016 Oct; 147(7):287-92. PubMed ID: 27423654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Therapy for Gender Transitions and Health Screenings in Transgender Older Adults.
    Mahan RJ; Bailey TA; Bibb TJ; Fenney M; Williams T
    J Am Geriatr Soc; 2016 Dec; 64(12):2554-2559. PubMed ID: 27996106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tibolone, oral or transdermal hormone replacement and colour Doppler analysis: a prospective, randomised pilot study.
    Battaglia C; Mancini F; Persico N; Penacchioni P; Regnani G; Volpe A; de Aloysio D
    Maturitas; 2004 Aug; 48(4):446-55. PubMed ID: 15283938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Replacement hormonal therapy: effects on ECG parameters in postmenopausal women].
    Zatikian EP; Smetnik VP; Klimenchenko NI
    Ter Arkh; 1998; 70(10):33-7. PubMed ID: 9864801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Radziszewski P; Szabłoński W
    Eur Urol; 2020 Mar; 77(3):393-394. PubMed ID: 31839489
    [No Abstract]   [Full Text] [Related]  

  • 26. EDITORIAL COMMENT.
    Sammon JD; Trinh QD
    Urology; 2019 Aug; 130():84-85. PubMed ID: 31345299
    [No Abstract]   [Full Text] [Related]  

  • 27. [Investigation on Clinical Course of Patients after Cessation of Long-Term Successful Hormone Monotherapy for Prostate Cancer].
    Uno M; Hattori S; Kato S; Masue N; Fujimoto Y
    Hinyokika Kiyo; 2016 Dec; 62(12):629-632. PubMed ID: 28103656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
    Ponholzer A; Loidl W; Bektic J; Dorfinger K; Hruby S; Jeschke K; Kramer G; Krause S; Ludvik G; Remzi M; Roider M; Stoiber F
    Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New anti-androgen and luteinizing hormone releasing hormone antagonist for the treatment of advanced prostate cancer].
    Furuya Y; Masai M
    Nihon Rinsho; 2000 Jul; 58 Suppl():317-9. PubMed ID: 11022739
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial.
    Ossewaarde ME; Dallinga-Thie GM; Bots ML; van der Schouw YT; Rabelink TJ; Grobbee DE; Westerveld HT
    Eur J Clin Invest; 2003 May; 33(5):376-82. PubMed ID: 12713450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia.
    Griebling TL
    J Urol; 2020 Nov; 204(5):1076. PubMed ID: 32845186
    [No Abstract]   [Full Text] [Related]  

  • 32. Background to and management of treatment-related bone loss in prostate cancer.
    Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
    Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tibolone: cancers of the breast and endometrium.
    Prescrire Int; 2006 Jun; 15(83):107. PubMed ID: 16764100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.
    Pezaro CJ; Mukherji D; De Bono JS
    Drug Discov Today; 2012 Mar; 17(5-6):221-6. PubMed ID: 22198164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone-dependence of prostatic cancer and principles of androgen deprivation.
    Neumann F
    Arch Ital Urol Androl; 1993 Dec; 65(6):633-45. PubMed ID: 8312946
    [No Abstract]   [Full Text] [Related]  

  • 36. Further fine tuning of hormone therapy.
    Goldenberg L
    J Urol; 2005 Aug; 174(2):415-6. PubMed ID: 16006855
    [No Abstract]   [Full Text] [Related]  

  • 37. Editorial Comment.
    Hamilton RJ
    J Urol; 2020 Jan; 203(1):126-127. PubMed ID: 31609669
    [No Abstract]   [Full Text] [Related]  

  • 38. Androgen deprivation therapy and cardiovascular risk.
    Rees J
    Practitioner; 2015 Sep; 259(1785):5. PubMed ID: 26591651
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to P. Ghadjar et al.
    Roy S; Malone S
    J Clin Oncol; 2020 May; 38(15):1747-1748. PubMed ID: 32209004
    [No Abstract]   [Full Text] [Related]  

  • 40. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.